Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$660M |
| 2 |
iShares Broad USD High Yield Corporate Bond ETF
USHY
|
+$173M |
| 3 |
Altria Group
MO
|
+$145M |
| 4 |
Verizon
VZ
|
+$134M |
| 5 |
United Parcel Service
UPS
|
+$124M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VanEck JP Morgan EM Local Currency Bond ETF
EMLC
|
+$181M |
| 2 |
iShares MSCI Germany ETF
EWG
|
+$148M |
| 3 |
Apple
AAPL
|
+$127M |
| 4 |
abrdn Physical Gold Shares ETF
SGOL
|
+$106M |
| 5 |
iShares Core S&P 500 ETF
IVV
|
+$92.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.3% |
| 2 | Financials | 12.48% |
| 3 | Healthcare | 11.72% |
| 4 | Consumer Discretionary | 11.3% |
| 5 | Industrials | 9.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2126
Nabors Industries
NBR
$1.24B
| $6.06M | ﹤0.01% |
104,000
+8,006
| +8% | +$353K |
|
2127
Construction Partners
ROAD
$6.03B
| $6.05M | ﹤0.01% |
207,976
+1,053
| +0.5% | +$25.2K |
|
|
TRHC
2128
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $6.04M | ﹤0.01% |
140,928
-4,742
| -3% | -$180K |
|
2129
Tompkins Financial
TMP
$1.46B
| $6M | ﹤0.01% |
84,949
+938
| +1% | +$59.4K |
|
2130
Artivion
AORT
$1.31B
| $5.99M | ﹤0.01% |
253,729
+8,757
| +4% | +$178K |
|
|
ATRI
2131
DELISTED
Atrion Corp
ATRI
| $5.99M | ﹤0.01% |
9,328
+175
| +2% | +$109K |
|
2132
TFS Financial
TFSL
$5.22B
| $5.99M | ﹤0.01% |
339,589
+4,267
| +1% | +$71K |
|
2133
Levi Strauss
LEVI
$9.43B
| $5.98M | ﹤0.01% |
297,760
+13,815
| +5% | +$247K |
|
|
NTUS
2134
DELISTED
Natus Medical Inc
NTUS
| $5.98M | ﹤0.01% |
298,308
-1,511
| -0.5% | -$29.6K |
|
2135
Krystal Biotech
KRYS
$9.61B
| $5.95M | ﹤0.01% |
99,179
+2,483
| +3% | +$124K |
|
2136
Lantheus
LNTH
$6.58B
| $5.95M | ﹤0.01% |
440,765
+2,523
| +0.6% | +$33K |
|
2137
Bally's
BALY
$664M
| $5.92M | ﹤0.01% |
117,845
+477
| +0.4% | +$16.7K |
|
|
SHOE
2138
Shoe Station Group
SHOE
$422M
| $5.92M | ﹤0.01% |
302,100
+4,984
| +2% | +$89.1K |
|
2139
Option Care Health
OPCH
$3.55B
| $5.91M | ﹤0.01% |
377,878
+44,959
| +14% | +$669K |
|
2140
Arcturus Therapeutics
ARCT
$177M
| $5.89M | ﹤0.01% |
135,830
+18,788
| +16% | +$1.27M |
|
|
CNST
2141
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $5.88M | ﹤0.01% |
203,961
+1,172
| +0.6% | +$29.5K |
|
2142
Atlanta Braves Holdings Series B
BATRK
$3.28B
| $5.85M | ﹤0.01% |
235,116
+3,452
| +1% | +$81.4K |
|
2143
GrafTech
EAF
$200M
| $5.85M | ﹤0.01% |
54,847
+12,785
| +30% | +$1.03M |
|
|
CAI
2144
DELISTED
CAI International, Inc.
CAI
| $5.82M | ﹤0.01% |
186,349
+15,439
| +9% | +$469K |
|
|
DEN
2145
DELISTED
Denbury Inc.
DEN
| $5.79M | ﹤0.01% |
+225,182
| New | +$4.57M |
|
2146
Omeros
OMER
$937M
| $5.76M | ﹤0.01% |
403,425
+6,453
| +2% | +$78.8K |
|
2147
Tidewater
TDW
$4.19B
| $5.75M | ﹤0.01% |
665,637
+36,662
| +6% | +$291K |
|
2148
Theravance Biopharma
TBPH
$875M
| $5.75M | ﹤0.01% |
323,578
+10,014
| +3% | +$180K |
|
2149
BioLife Solutions
BLFS
$1.59B
| $5.73M | ﹤0.01% |
143,737
+5,260
| +4% | +$179K |
|
|
NVEE
2150
DELISTED
NV5 Global
NVEE
| $5.69M | ﹤0.01% |
289,008
+2,908
| +1% | +$48.9K |
|
Similar funds
Charles Schwab's Q4 2020 Portfolio in Review
As of Q4 2020, Charles Schwab held 3,457 positions worth $252B, up 16% from $217B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Charles Schwab's Q4 2020 filing shows 113 new, 2,243 increased, 711 reduced and 62 closed positions. Its largest new stake was Vanguard FTSE Pacific ETF: 993,047 shares worth $79M. The largest sale was VanEck JP Morgan EM Local Currency Bond ETF, an estimated $181M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q4 2020 buy was Vanguard FTSE Pacific ETF: 993,047 shares worth $79M.
- Charles Schwab added most to Tesla in Q4 2020, an estimated $660M increase.
- Charles Schwab's biggest Q4 2020 reduction was VanEck JP Morgan EM Local Currency Bond ETF, cutting an estimated $181M.
- Charles Schwab fully exited iShares MSCI Germany ETF in Q4 2020, selling an estimated $148M.
- Charles Schwab's ten largest holdings make up 17% of its $252B portfolio in Q4 2020.
- Charles Schwab opened 113 new positions and closed 62 in Q4 2020.
- Charles Schwab's portfolio value rose 16% quarter-over-quarter to $252B.
Based on Charles Schwab's 13F filing for Q4 2020, filed 16 Feb 2021.